Declining trends of diabetic nephropathy, retinopathy and neuropathy with improving diabetes care indicators in Japanese patients with type 2 and type 1 diabetes (JDDM 46)

Hiroki Yokoyama,1 Shin-ichi Araki,2 Koichi Kawai,3 Katsuya Yamazaki,3 Osamu Tomonaga,4 Shin-ichiro Shirabe,5 Hiroshi Maegawa,2 for the JDDM study group

To cite: Yokoyama H, Araki S, Kawai K, et al. Declining trends of diabetic nephropathy, retinopathy and neuropathy with improving diabetes care indicators in Japanese patients with type 2 and type 1 diabetes (JDDM 46). BMJ Open Diab Res Care 2018;6:e000521. doi:10.1136/bmjdrcc-2018-000521

ABSTRACT

Objective We examined changes in prevalence of diabetic microvascular/macrovascular complications and diabetes care indicators for adults in Japan with type 2 and type 1 diabetes over one decade.

Research design and methods Two independent cohorts were recruited with the same inclusion criteria in 2004 (cohort 1: 3319 with type 2 and 286 with type 1 diabetes) and in 2014 (cohort 2: 3932 with type 2 and 308 with type 1 diabetes). Prevalence of complications and care indicators including achieving treatment targets for glycemia, blood pressure, lipid control, body mass index (BMI), and smoking were compared. In addition, patients in cohort 1 were re-examined in 2014 and their data were compared with the baseline data of each cohort.

Results In type 2 diabetes, the prevalence of nephropathy, retinopathy, neuropathy, chronic kidney disease, current smoking and stroke significantly decreased, with improvements in achieving treatment target rates in cohort 2 two as compared with cohort 1. In type 1 diabetes, the prevalence of nephropathy, retinopathy, chronic kidney disease, and hemoglobin A1C values significantly decreased. Decreases in prevalence of microvascular complications in type 2 diabetes were similarly found in each age-matched and sex-matched group, whereas younger patients exhibited marked increase in BMI and lower treatment target achieving rates compared with elderly patients. Regarding normoalbuminuric renal impairment, only a slight increase in the prevalence was observed both in type 2 and type 1 diabetes. In cohort 1, re-examined in 2014, care indicators were significantly improved from 2004, while complications decreased with getting 10 years older.

Conclusions We observed declining trends of diabetic microvascular complications with improvement in diabetes care indicators in type 2 and type 1 diabetes. Younger patients with type 2 diabetes exhibited marked increase in BMI and lower rates of achieving treatment targets compared with elderly patients, which remains a concern.

INTRODUCTION

Type 2 diabetes is pandemic and represents a major threat to public health in many countries of the world. With the expected increase in the prevalence of diabetes due to increasing rates of obesity and decreased physical activity, the burden of diabetic microvascular...
complications, known as diabetic nephropathy, retinopathy, or neuropathy, may also increase. These three microvascular complications are life-threatening because they themselves are the risk factors for cardiovascular disease (CVD) and premature death, and could lead to end-stage renal disease, blindness and autonomic neuropathy. In order to prevent microvascular complications and CVD, individualized glycemic control and multifactorial risk reduction are the cornerstones of high-quality diabetes care, as demonstrated in many clinical trials.

Optimal individualized diabetes management has been promoted until now and the achievement of diabetes care indicators has been assessed. Secular changes in diabetes care indicators have been reported in the USA, Canada, Germany, and China. In these reports, care for diabetes has been generally improving, although it depended on the area and the time examined. However, secular changes in the prevalence of microvascular complications have not been adequately assessed and those in type 1 diabetes have not yet been reported.

In Japan, approximately 10 million individuals among the total population of 125 million have diabetes. Treatment goals for patients with diabetes have been set by national guidelines from the Japan Diabetes Society (JDS) since 2002, while most of the patients have been treated in primary care settings. Tracking the changes in prevalence of complications and the quality of care indicators at the population level is essential to help understand successes and failures and to direct quality improvement initiatives and health policies. To date, no studies have comprehensively evaluated the prevalence of complications and the quality of diabetes care over time at the national level.

In this study, we examined changes in prevalence of complications and quality of care indicators for adults in Japan with type 2 and type 1 diabetes collected in 2004 and 2014. Complications included both microvascular and macrovascular diseases, and diabetes care indicators included rate of achieving treatment targets for glycemia, blood pressure (BP), lipid control, body weight, and smoking.

**RESEARCH DESIGN AND METHODS**

**Study population**

**JDDM Study group**

This study was a nationwide multicenter study conducted by the Japan Diabetes Clinical Data Management (JDDM) Study group. This study group was organized by general practitioners voluntarily gathering from all over Japan in order to elucidate the actual status of Japanese diabetes care and promote clinical diabetes research based on daily clinical practice in 2001 because there was no nationwide registry system in Japan. The majority of physicians in this study were the practitioners conducting daily general practice while specializing in or being particularly interested in diabetes care (see appendix). In this study group, all medical records on daily clinical practice, such as patient information, clinical data, medical precipitation history and so on, were accumulated over time at the central office using the same software so as to collect these data.

**Cohort recruitment**

Two independent cohorts were recruited in 2004 as cohort 1 and in 2014 as cohort 2 for the purpose of evaluating the risk of CVD and death in patients with diabetes in a prospective fashion. The inclusion criteria for the two cohorts were the same; age from 20 years to 70 years, being regularly treated for diabetes for more than 1 year prior to the baseline, and having type 2 or type 1 diabetes. Those who were pregnant or had gestational diabetes were not included. A patient who participated in cohort 1 was not allowed to enter cohort 2, thus no patients overlapped. Seventeen and 28 clinics participated in cohort 1 and cohort 2, respectively, of which 10 clinics participated in both cohorts.

The present study was primarily designed to investigate the trend of the prevalence of microvascular/macrovascular disease and diabetes care indicators by comparing the baseline clinical features of two different 10-year cohorts. In addition, patients in cohort 1 were re-examined in 2014 and their data were compared with the baseline data of each cohort to ensure the trend. Patients in our cohorts were treated with the aim of achieving the targets recommended by JDS: a glycated hemoglobin $A_1c$ (HbA1c) value of <7.0% (53 mmol/mol), BP <130/80 mm Hg, serum concentrations of low-density lipoprotein cholesterol <3.1 mmol/L (120 mg/dL), high-density lipoprotein (HDL) cholesterol ≥1.0 mmol/L (40 mg/dL), and non-HDL cholesterol <3.8 mmol/L (150 mg/dL), and body mass index (BMI) of 20–24 kg/m². Lipid on target was defined as meeting all three levels. All participants provided written informed consent.

**Measurements**

Diabetes was diagnosed according to the JDS criteria. Briefly, type 1 diabetes was defined as a definitive requirement for insulin treatment in less than 1 year following diagnosis. Type 2 diabetes was defined by absence of ketoacidosis and glycemic control without insulin treatment for at least 2 years after diagnosis, and patients were divided into treatment groups by diet alone, hypoglycemic tablets, or insulin with or without using tablets. BMI was calculated as the ratio of body weight (kg) and height (m) squared. BP was measured with an appropriately sized cuff in the sitting position using an automated standardized BP device. Non-fasting blood samples were drawn and analyzed to measure serum creatinine (Cr) and lipids at local laboratories. HbA1c levels were measured at each clinic by high performance liquid chromatography and presented as National Glycohemoglobin Standardization Program values, according to the recommendations of the JDS. Serum and urinary concentrations of Cr and urinary albumin were measured by enzymatic methods and turbidimetric immunoassay, respectively.
The urinary albumin excretion rate was recorded as the albumin-to-creatinine ratio (ACR). Normoalbuminuria, microalbuminuria and macroalbuminuria were defined as an ACR <30 mg/g Cr, ACR ≥30 mg/g Cr and <300 mg/g Cr, and ACR ≥300 mg/g Cr, respectively, in two of three spot urine specimens. The glomerular filtration rate (GFR) was estimated using the following equation by the Japanese Society of Nephrology: eGFR (ml/min/1.73 m^2) = 194 × Scr^−1.094 × Age^−0.287 × 0.739 (if female). According to the classification defined by Kidney Disease Improving Global Outcomes (KDIGO), patients were divided by the ACR (normoalbuminuria, microalbuminuria, and macroalbuminuria) and eGFR (≥90, 60–89, and <60) levels.23

Diabetic microvascular complications included nephropathy, retinopathy and neuropathy. Diabetic nephropathy was defined as ACR ≥30 mg/g Cr. Chronic kidney disease (CKD) was defined as ACR ≥30 mg/g Cr or eGFR <60 mL/min/1.73 m^2. Diabetic retinopathy was diagnosed by ophthalmologists after pupillary dilatation with fundus photography, which was defined as presence of any retinopathy. Neuropathy was diagnosed in patients with two or more of three components, as recommended in the simplified diagnostic criteria proposed by the Diabetic Neuropathy Study Group in Japan:24 (1) Subjective symptoms in the bilateral lower limbs or feet. (2) Loss of or decreased ankle jerk reflex. (3) Decreased vibration perception, assessed using a C128 tuning fork and bilaterally measured at the medial malleoli. Neuropathic symptoms were defined as bilateral spontaneous pain, hypoesthesia including decreased perception to pinprick and temperature (cold tuning fork), or paresthesia of the legs. Macrovascular complications, that is, CVD, consisted of coronary artery disease (CAD), ischemic stroke, and peripheral artery disease (PAD). CAD included myocardial infarction, angina pectoris, and coronary interventions. Ischemic stroke included symptomatic brain infarction and carotid revascularization and did not include silent brain infarction, transient ischemic attack or brain hemorrhage. PAD was diagnosed when intermittent claudication occurred, with the confirmation of an ankle-brachial pressure index <0.9 that was measured automatically by volume-plethysmographic apparatus or significant peripheral artery stenosis by angiography, or leg amputation above the ankle as a result of diabetes. Smoking was defined as never/past/current.

Statistical analysis
The differences in clinical characteristics between cohort 1 and cohort 2 were analyzed, in which the significance of differences between groups was assessed by χ² tests for categorical variables and the Student’s t-test for continuous variables. BMI, smoking, percentage of achieving treatment target for HbA1c, BP and lipid were compared according to the age-matched and sex-matched groups. The data of cohort 1 re-examined in 2014 were compared with their data in 2004 and with data of cohort 2, in which comparison of continuous variables of the same individuals between 2004 and 2014 was performed by paired t-test. Data were expressed as mean±SD if normally distributed. A p value of less than 5% (two-tailed) was considered significant. All analyses were performed with the statistical software package SPSS (SPSS Japan, Tokyo, Japan).

RESULTS
Table 1 shows the clinical characteristics of patients with type 2 and type 1 diabetes compared between cohort 1 and cohort 2. In type 2 diabetes, the age was similar and cohort 2 had more percentage of male, longer duration, higher BMI, higher percentage of using tablets with lower percentages of diet only and insulin-use, and lower percentage of current smokers. The rates of achieving treatment targets for HbA1c, BP and lipid were all significantly higher in cohort 2, in which HbA1c improved in all groups of diet/tablets/insulin, and BP and lipid improved only in users of antihypertensive and lipid-lowering drugs, respectively. Regarding the comparison of the drugs for diabetes, hypertension and dyslipidemia between the two cohorts, cohort 2 was characterized by increased use of metformin and glinide and decreased use of sulfonylureas; increased use of ultra-long acting and decreased use of NPH, Mix, and short-acting insulin; and increased use of angiotensin receptor blockers, calcium channel blockers, diuretics, β-blockers, and statins and decreased use of ACE inhibitors and α-blockers. In type 1 diabetes, gender, age, and duration were the same, and the value for HbA1c was significantly lower in cohort 2. The trend of insulin use in type 1 diabetes was similar to that in type 2 diabetes and the use of ultra-short acting insulin increased.

Prevalence of microvascular and macrovascular complications compared between cohort 1 and cohort 2 for patients with type 2 and type 1 diabetes is shown in figure 1. In type 2 diabetes, the prevalence of three microvascular complications, CKD, and ischemic stroke were significantly lower in cohort 2, whereas that of CAD and PAD did not differ between the cohorts. In type 1 diabetes, prevalence of nephropathy, retinopathy, and CKD were significantly lower in cohort 2. Rates of having all three microvascular complications in cohort 1 versus cohort 2 were 7.8% versus 4.7% (p<0.001) in type 2 diabetes, and 4.6% versus 3.9% in type 1 diabetes.

Because different clinics participated in the two cohorts, the effect of interclinic differences on the above results cannot be excluded. Therefore, the analysis limited to 10 clinics that participated in both cohorts was performed (online supplementary table 1), and it indicated the same trend as table 1 and figure 1.

Table 2 shows the differences between the two cohorts in type 2 diabetes regarding BMI, smoking, rates of achieving targets for HbA1c, BP, lipid, prevalence of microvascular and macrovascular complications according to the groups by sex and age. In male patients, BMI values for ages <54 years, 54–59 years and 60–64
Table 1: Comparison between cohort 1 and cohort 2 for patients with type 2 and type 1 diabetes with respect to clinical characteristics, controlled levels of blood glucose, BP, and lipid, and treatments for diabetes, hypertension, and dyslipidemia. Cohorts 1 and 2 were recruited in 2004 and 2014, respectively, with the same inclusion criteria without any overlapping patients between the cohorts.

|                      | Type 2 diabetes |          | Type 1 diabetes |          |          | Data availability (%) |
|----------------------|-----------------|----------|-----------------|----------|----------|-----------------------|
|                      | Cohort 1 (n=3319) | Cohort 2 (n=3932) | Cohort 1 (n=286) | Cohort 2 (n=308) |          |                      |
| Male (%)             | 64.2*           | 42.0     | 68.8*           | 40.9     | 100.0    |                      |
| Age (years)          | 58.3±8.3        | 58.6±8.7 | 45.2±13.0       | 43.6±13.5 | 100.0    |                      |
| Known duration (years) | 11±8           | 12±8*    | 14±9            | 15±10    | 100.0    |                      |
| BMI (kg/m²)          | 24.7±3.8        | 25.4±4.2* | 22.5±3.2        | 22.9±3.1 | 100.0    |                      |
| Diet/tablets/insulin (%) | 13.9/64.8/21.3  | 9.7/70.8/19.5* | –              | –        | 100.0    |                      |
| Smoking Never/past/current (%) | 47.9±30.9/31.2 | 41.7/33.3/25.0* | 52.4±17.1/30.4 | 58.8±16.2/25.0 | 99.7    |                      |
| HbA₁c, mmol/mol (%)  | 58±8 (7.46±1.09) | 52±7 (7.00±0.95)* | 62±9 (7.91±1.22) | 60±8 (7.68±1.04)‡ | 100.0    |                      |
| HbA₁c on target (%)  | 33.6            | 23.4     | 57.1*           | 26.1     | 100.0    |                      |
| with diet alone (%)  | 66.5            | 80.6*    | –              | –        | 100.0    |                      |
| with oral hypoglycemic tablets (%) | 31.8         | 61.4*    | –              | –        | 100.0    |                      |
| with insulin (%)     | 17.6            | 29.9*    | –              | –        | 100.0    |                      |
| Systolic BP (mm Hg)  | 129±14          | 127±14*  | 122±16          | 122±15   | 100.0    |                      |
| Diastolic BP (mm Hg) | 75±9            | 75±10    | 72±9            | 72±10    | 100.0    |                      |
| Use of antihypertensive drugs (%) | 38.7        | 48.0*    | –              | –        | 100.0    |                      |
| BP on target (%)     | 42.2            | 62.2†    | 46.2†           | 62.3     | 100.0    |                      |
| without antihypertensive drugs (%) | 51.2        | 68.7     | 57.8            | 68.4     | 100.0    |                      |
| BP on target (%)     | 27.9            | 27.9     | 40.7*           | 37.7     | 100.0    |                      |
| LDL (mg/dl)          | 116±29          | 108±28*  | 102±27          | 107±28   | 98.0     |                      |
| HDL (mg/dl)          | 55±15           | 55±15    | 70±19           | 72±18    | 99.7     |                      |
| non-HDL (mg/dl)      | 145±33          | 132±33*  | 123±29          | 124±31   | 95.5     |                      |
| Use of lipid-lowering drugs (%) | 23.7        | 45.3*    | –              | –        | 100.0    |                      |
| Lipid on target (%)  | 42.5            | 68.7     | 54.4*           | 66.6     | 97.1     |                      |
| without lipid-lowering drugs | 42.7        | 71.3     | 45.5            | 65.3     | 97.2     |                      |
| with lipid-lowering drugs | 42.0        | 50.0     | 54.4*           | 75.0     | 97.0     |                      |
| All of HbA₁c, BP and lipids on targets (%) | 7.3        | 9.5      | 15.5*           | 12.1     | 99.0     |                      |
| Non-insulin antidiabetic tablets | 100.0     |          |          |          |          |                      |
| Sulfonylureas         | 57.4            | 34.1*    | –              | –        | 100.0    |                      |
| Metformin            | 42.3            | 45.7*    | –              | –        | 100.0    |                      |
| Pioglitazone         | 11.7            | 12.5     | –              | –        | 100.0    |                      |
| Glinide              | 5               | 6.3*     | –              | –        | 100.0    |                      |
| α-glucosidase inhibitors | 13.7         | 13.7     | 3.8            | 3.6      |          |                      |
| Dipeptidyl peptidase-4 inhibitors | –            | 55.0     | –              | –        | 100.0    |                      |
| SGLT-2 inhibitors    | –               | –        | –              | –        | 100.0    |                      |
| total number of tablets per user | 1.7±0.8    | 2.1±1.0* | 1.3±0.5        | 1.4±0.7  | 100.0    |                      |
| GLP-1 agonist        | –               | 3.3      | –              | –        | 100.0    |                      |
| Insulin              | 100.0           |          |          |          |          |                      |
| Ultra-long-acting    | 3.9             | 12.5*    | 46.2           | 86.4*    | 100.0    |                      |
| NPH                  | 6.7             | 0.3*     | 34.3           | 1.0*     | 100.0    |                      |
| Mix                  | 9.5             | 5.2*     | 14.7           | 5.8*     | 100.0    |                      |
| Short-acting         | 2.3             | 0.2*     | 23.8           | 2.9*     | 100.0    |                      |
| Ultra-short-acting   | 8.9             | 9.0      | 68.2           | 89.9*    | 100.0    |                      |
| Antihypertensive drugs | 100.0       |          |          |          |          |                      |
| Angiotensin receptor blockers | 22.6        | 40.4*    | 8.0           | 16.6†    | 100.0    |                      |

Continued
### Table 1 Continued

|                      | Type 2 diabetes |                      | Type 1 diabetes |                      | Data availability (%) |
|----------------------|-----------------|----------------------|-----------------|----------------------|-----------------------|
|                      | Cohort 1        | Cohort 2             | Cohort 1        | Cohort 2             |                       |
| n=3319               | n=3932          | n=286                | n=308           |                      |                       |
| ACE inhibitors       | 4.5             | 2.9*                 | 3.1             | 1.0                 |                       |
| Calcium channel blockers | 23.9           | 27.1†                | 7.0             | 12.3‡               |                       |
| Diuretics            | 5.9             | 9.0*                 | 1.0             | 2.9                 |                       |
| β-blockers           | 4.6             | 6.0†                 | 2.1             | 1.3                 |                       |
| α-blockers           | 2.9             | 1.1*                 | 0               | 0.6                 |                       |
| Others               | 0.8             | 1.2                  | 0               | 0.3                 |                       |
| total number of drugs per user | 1.7±0.9       | 1.8±0.9*             | 1.4±0.7         | 1.8±0.8‡             |                       |
| Antihyperlipidemic drugs |              |                      |                 | 97.1                |                       |
| Statins              | 18.1            | 39.3*                | 10.5            | 13.0                |                       |
| Fibrates             | 4.9             | 4.6                  | 1.7             | 0                   |                       |
| total number of drugs per user | 1.0±0.2       | 1.1±0.2‡             | 1.0±1.2         | 1.1±0.2              |                       |

* p<0.001.  † p<0.01.  ‡ p<0.05 versus cohort 1.
BMI, body mass index; BP, blood pressure; HbA1c, hemoglobin A1C; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SGLT-2, sodium glucose cotransporter-2.

years were significantly higher in cohort 2 than in cohort 1, and the same trend was observed in female patients. The percentage of current smokers decreased in all age groups of cohort 2 for male patients, whereas it increased in all age groups of cohort 2 for female patients. The rate on HbA1c target was significantly higher in cohort 2 in

![Figure 1](http://drc.bmj.com/)  
* a) p<0.001 vs. Cohort 1  
* b) p<0.01 vs. Cohort 1  
* c) p<0.05 vs. Cohort 1

Figure 1  Prevalence of microvascular and macrovascular complications compared between cohort 1 and cohort 2 for subjects with type 2 (A, upper panel) and type 1 (B, lower panel) diabetes. CAD, coronary artery disease; CKD, chronic kidney disease; PAD, peripheral artery disease.
Table 2  Comparison of BMI, smoking, and percentage of HbA1c on target, BP on target, lipid on target, and prevalence of microvascular and macrovascular complications between the two cohorts in patients with type 2 diabetes stratified by age and sex. Changes of rates of achieving the targets and prevalence from cohort 1 to cohort 2 were given in parentheses.

| Age         | Male Cohort 1 | Male Cohort 2 | P values | Female Cohort 1 | Female Cohort 2 | P values |
|-------------|---------------|---------------|----------|-----------------|-----------------|----------|
| N           |               |               |          |                 |                 |          |
| <54 years   | 591           | 768           |          | 236             | 235             |          |
| 54–59 years | 586           | 509           |          | 334             | 215             |          |
| 60–64 years | 526           | 693           |          | 290             | 333             |          |
| ≥65 years   | 428           | 734           |          | 328             | 445             |          |
| BMI kg/m²   |               |               |          |                 |                 |          |
| <54 years   | 25.9±4.1      | 27.2±4.6      | <0.001   | 26.0±4.5        | 27.0±5.8        | <0.05    |
| 54–59 years | 24.5±3.1      | 25.7±3.9      | <0.001   | 24.6±4.1        | 25.7±4.9        | <0.01    |
| 60–64 years | 23.8±2.8      | 24.7±3.4      | <0.001   | 24.5±4.2        | 24.7±4.3        | NS       |
| ≥65 years   | 24.2±3.2      | 24.2±3.0      | NS       | 24.9±4.1        | 24.3±4.1        | NS       |
| Smoking     |               |               |          |                 |                 |          |
| Never/past/current (%) |         |               |          |                 |                 |          |
| <54 years   | 25.5/22.3/52.1| 31.5/28.9/39.6| <0.001   | 77.1/6.8/16.1   | 64.8/14.6/20.6 | <0.01    |
| 54–59 years | 25.6/25.6/48.7| 19.6/45.7/34.8| <0.001   | 83.2/6.6/10.2   | 73.4/14.0/12.6 | <0.01    |
| 60–64 years | 28.5/33.7/37.8| 24.6/46.7/28.7| <0.001   | 84.8/6.9/8.3    | 78.8/12.7/8.5  | NS       |
| ≥65 years   | 33.9/35.0/31.1| 24.5/51.8/23.7| <0.001   | 87.5/7.9/4.6    | 85.1/9.8/5.0   | NS       |
| HbA₁c on target (%) |         |               |          |                 |                 |          |
| <54 years   | 30.3          | 50.5 (+20.2)  | <0.001   | 30.1            | 49.4 (+19.3)    | <0.001   |
| 54–59 years | 33.8          | 58.7 (+24.9)  | <0.001   | 29.9            | 58.6 (+28.7)    | <0.001   |
| 60–64 years | 40.5          | 60.2 (+19.7)  | <0.001   | 28.6            | 51.1 (+22.5)    | <0.001   |
| ≥65 years   | 39.7          | 62.9 (+23.2)  | <0.001   | 30.8            | 60.1 (+29.3)    | <0.001   |
| BP on target (%) |         |               |          |                 |                 |          |
| <54 years   | 40.9          | 38.9 (-2.0)   | NS       | 57.2            | 54.0 (-3.2)     | NS       |
| 54–59 years | 43.3          | 41.1 (-2.2)   | NS       | 41.6            | 51.2 (+9.6)     | <0.05    |
| 60–64 years | 40.3          | 47.3 (+7.0)   | <0.05    | 42.4            | 51.7 (+9.3)     | <0.05    |
| ≥65 years   | 38.8          | 45.0 (+6.2)   | <0.05    | 39.3            | 54.6 (+15.3)    | <0.001   |
| Lipid on target (%) |         |               |          |                 |                 |          |
| <54 years   | 32.7          | 41.8 (+9.1)   | <0.01    | 44              | 48.7 (+4.7)     | NS       |
| 54–59 years | 45.1          | 58.4 (+13.3)  | <0.001   | 38.2            | 55.4 (+17.2)    | <0.001   |
| 60–64 years | 49.8          | 58.1 (+8.3)   | <0.01    | 39.2            | 57.8 (+18.6)    | <0.001   |
| ≥65 years   | 45.5          | 58.9 (+13.4)  | <0.001   | 46.0            | 58.8 (+12.8)    | <0.01    |
| Nephropathy (%) |         |               |          |                 |                 |          |
| <54 years   | 30.6          | 23.2 (-7.4)   | <0.01    | 33.2            | 19.2 (-14.0)    | <0.01    |
| 54–59 years | 32.8          | 25.0 (-7.8)   | <0.01    | 26.3            | 18.6 (-7.7)     | <0.05    |
| 60–64 years | 35.4          | 25.6 (-9.8)   | <0.001   | 28.6            | 16.2 (-12.4)    | <0.001   |
| ≥65 years   | 35.7          | 24.3 (-11.4)  | <0.001   | 36.9            | 17.1 (-19.8)    | <0.001   |
| Retinopathy (%) |         |               |          |                 |                 |          |
| <54 years   | 25.9          | 18.8 (-7.1)   | <0.01    | 30.6            | 23.3 (-7.3)     | NS       |
| 54–59 years | 29.2          | 20.9 (-8.3)   | <0.01    | 34.2            | 26.9 (-7.3)     | NS       |
| 60–64 years | 33.7          | 23.9 (-9.8)   | <0.001   | 33.7            | 29.1 (-4.6)     | NS       |
| ≥65 years   | 32.1          | 24.6 (-7.5)   | <0.01    | 33.5            | 26.8 (-6.7)     | <0.05    |
| Neuropathy (%) |         |               |          |                 |                 |          |
| <54 years   | 16.0          | 8.4 (-7.6)    | <0.001   | 19.6            | 12.5 (-7.1)     | <0.05    |

Continued
Table 2

Pathophysiology/Complications

| Age          | Male Cohort 1 | Male Cohort 2 | P values | Female Cohort 1 | Female Cohort 2 | P values |
|--------------|---------------|---------------|----------|------------------|-----------------|----------|
| 54–59 years  | 20.4          | 14.0 (–6.4)   | <0.01    | 21.8             | 15.3 (–6.5)     | NS       |
| 60–64 years  | 25.5          | 16.4 (–9.1)   | <0.001   | 30.2             | 18.4 (–11.8)    | <0.01    |
| ≥65 years    | 27.0          | 21.3 (–5.7)   | <0.05    | 26.8             | 24.4 (–2.4)     | NS       |

CAD (%)

| Age          | Male Cohort 1 | Male Cohort 2 | P values | Female Cohort 1 | Female Cohort 2 | P values |
|--------------|---------------|---------------|----------|------------------|-----------------|----------|
| <54 years    | 2.2           | 2.8 (+0.6)    | NS       | 3.0              | 0.4 (–2.6)      | <0.05    |
| 54–59 years  | 4.8           | 5.8 (+1.0)    | NS       | 3.0              | 2.0 (–1.0)      | NS       |
| 60–64 years  | 6.5           | 7.0 (+0.5)    | NS       | 2.4              | 2.7 (+0.3)      | NS       |
| ≥65 years    | 11.9          | 8.5 (–3.4)    | NS       | 7.6              | 4.9 (–2.7)      | NS       |

Stroke (%)

| Age          | Male Cohort 1 | Male Cohort 2 | P values | Female Cohort 1 | Female Cohort 2 | P values |
|--------------|---------------|---------------|----------|------------------|-----------------|----------|
| <54 years    | 2.2           | 0.8 (–1.4)    | <0.05    | 0.9              | 1.3 (+0.4)      | NS       |
| 54–59 years  | 3.8           | 2.2 (–1.6)    | NS       | 3.0              | 2.3 (–0.7)      | NS       |
| 60–64 years  | 6.9           | 3.6 (–3.3)    | <0.05    | 4.6              | 2.1 (–2.5)      | NS       |
| ≥65 years    | 10.8          | 6.1 (–4.7)    | <0.01    | 6.8              | 2.9 (–3.9)      | <0.05    |

BMI, body mass index; BP, blood pressure; CAD, coronary artery disease; HbA1c, hemoglobin A1c; NS, not significant.

Table 3

| Type 2 diabetes | Cohort 1 | Cohort 2 | Total | Type 1 diabetes | Cohort 1 | Cohort 2 | Total |
|-----------------|----------|----------|-------|-----------------|----------|----------|-------|
| GFR ≥90         | 15.4     | 6.5      | 1.2   | 23.1            | 17.8     | 3.9      | 0.4   | 22.1            | 27.0     | 4.9      | 0.4   | 32.3            | 39.6     | 3.0      | 0.3   | 42.9*          |
| GFR 60–89       | 45.1     | 13.7     | 3.3   | 62.1            | 52.1     | 10.3     | 2.0   | 64.4            | 50.2     | 7.0      | 3.5   | 60.7            | 44.9     | 5.6      | 0.0   | 50.5           |
| GFR <60         | 6.9      | 3.9      | 4.0   | 14.8            | 7.9      | 3.2      | 2.5   | 13.6            | 2.8      | 1.4      | 2.8   | 7.0            | 3.3      | 0.7      | 2.6   | 6.6            |
| Total           | 67.4     | 24.1     | 8.5   | 100.0           | 77.8†    | 17.4     | 4.9   | 100.0           | 80.0     | 13.3     | 6.7   | 100.0          | 87.8‡    | 9.2      | 3.0   | 100.0          |

Percentages are given.

*<p<0.001;
†<p<0.05 by χ² test (3×2) to analyze the distribution of albuminuria categories (three groups) between cohort 1 and cohort 2 in type 2 diabetes, respectively.
‡<p<0.05 by χ² test (3×2) to analyze the distribution of albuminuria categories (three groups) between cohort 1 and cohort 2 in type 1 diabetes.
GFR, glomerular filtration rate; KDIGO, Kidney Disease Improving Global Outcomes.
Pathophysiology/Complications

categories were significantly different (p<0.05), in which percentage of eGFR ≥90 were higher in cohort 2. Proportion of normalalbuminuria with eGFR <60, that is, normalalbuminuric CKD, showed a slight increase from 6.9% to 7.9% in type 2 diabetes, and from 2.8% to 3.3% in type 1 diabetes.

In cohort 1, 2824 patients with type 2 diabetes (85.1%) and 218 patients with type 1 diabetes (76.2%) were continuously followed until 2014 and their clinical characteristics in 2014 were compared with their baseline data (in 2004) or those in cohort 2 (in 2014), as shown in table 4. Baseline data of these patients in 2004 were similar to those of the 3319 patients with type 2 diabetes and 286 patients with type 1 diabetes, respectively. In type 2 diabetes, the rates on target HbA1c, BP and lipid were significantly higher in 2014 than baseline data in

| Table 4 | Clinical characteristics, controlled levels of blood glucose, BP and lipid, and prevalence of microvascular and macrovascular complications in patients with type 2 and type 1 diabetes in cohort 1, which were re-examined in 2014. Ascertainment rate was 85.1% (2824/3319) for type 2 diabetes and 76.2% (218/286) for type 1 diabetes, respectively |
|---------|----------------------------------------------------------------------------------|
|          | Type 2 diabetes                                                                 |
|          | Cohort 1 in 2014  | P value  | Type 1 diabetes  | Cohort 1 in 2014 |
|          | n=2824              | versus cohort 1 in 2004  | versus cohort 2 in 2014 | n=218     | versus cohort 1 in 2004  | versus cohort 2 in 2014 |
| Male (%) | 63.4                 | NS       | 43.1             | NS       |
| Age (years) | 67.7±8.2             | <0.001   | 55.0±12.3        | <0.001   | <0.001  |
| Known duration (years) | 21±8             | <0.001   | 24±9             | <0.001   | <0.001  |
| BMI (kg/m²) | 24.2±4.0             | <0.001   | 22.9±4.0         | <0.05    | NS      |
| Diet/tablets/insulin (%) | 8.1/63.2/28.7       | <0.001   | <0.001           | –        | –       |
| HbA₁c, mmol/mol (%) | 56±7 (7.17±0.93)     | <0.001   | 60±8 (7.66±1.07) | <0.01    | NS      |
| HbA₁c on target (%) | 45.2                | <0.001   | 26.6             | NS       | NS      |
| with diet alone (%) | 63.0               | NS       | <0.001           | –        | –       |
| with oral hypoglycemic tablets (%) | 49.8               | <0.001   | <0.001           | –        | –       |
| with insulin | 30.1                | <0.001   | NS               | –        | –       |
| Systolic BP (mm Hg) | 128±14              | <0.05    | 125±16           | <0.05    | NS      |
| Diastolic BP (mm Hg) | 71±10               | <0.001   | 71±11            | NS       | NS      |
| Use of antihypertensive drugs (%) | 49.4               | <0.001   | 32.6             | <0.001   | <0.01  |
| BP on target (%) | 44.9                | <0.05    | 50.0             | <0.01    | <0.01  |
| without antihypertensive drugs (%) | 46.8               | <0.05    | 55.5             | <0.01    | <0.05  |
| with antihypertensive drugs (%) | 43.0                | <0.001   | 38.6             | NS       | NS      |
| LDL (mg/dl) | 106±26              | <0.001   | 105±27           | NS       | NS      |
| HDL (mg/dl) | 56±16               | <0.001   | 68±18            | <0.01    | <0.05  |
| non-HDL (mg/dl) | 130±29              | <0.001   | 125±29           | NS       | NS      |
| Use of lipid-lowering drugs (%) | 38.2               | <0.001   | 25.7             | <0.01    | <0.01  |
| Lipid on target (%) | 54.4                | <0.001   | 61.8             | NS       | <0.01  |
| without lipid-lowering drugs (%) | 47.0                | <0.05    | 61.9             | NS       | <0.05  |
| with lipid-lowering drugs (%) | 65.8                | <0.001   | 61.7             | NS       | NS      |
| All of A1c, BP and lipids on targets (%) | 12.1               | <0.001   | 9.0              | NS       | NS      |
| Normoalbuminuria/microalbuminuria / macroalbuminuria (%) | 70.9/24.0/5.1 | <0.001 | 84.6/11.8/3.6   | NS       | NS      |
| CKD (%) | 50.5                | <0.001   | 28.2             | NS       | <0.01  |
| Retinopathy (%) | 35.5                | <0.001   | 40.6             | NS       | <0.001 |
| Neuropathy (%) | 28.8                | <0.001   | 20.9             | NS       | <0.01  |
| CAD (%) | 12.6                | <0.001   | 5.7              | <0.05    | NS      |
| Ischemic stroke (%) | 6.8                 | <0.01    | 2.2              | NS       | NS      |

Analysis between continuous values in 2004 and in 2014 of cohort 1 patients was performed by paired t-test. ACR, albumin-to-creatinine ratio; BMI, body mass index; BP, blood pressure; CAD, coronary artery disease; CKD; chronic kidney disease (ACR ≥30 or eGFR <60); eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A₁c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NS, not significant.
2004, but did not reach the levels of cohort 2. Regarding complications, the significant decrease of nephropathy was observed, while the prevalence of retinopathy, neuropathy, CKD, CAD and stroke significantly increased in 2014. In type 1 diabetes, HbA1c values and the rate on BP target were significantly improved. The increase in prevalence of CAD from 2004 to 2014 reached a statistical significance.

**DISCUSSION**

In this study, we examined secular trends in prevalence of microvascular/macrovascular complications and diabetes care indicators in patients with type 2 and type 1 diabetes. In type 2 diabetes, we found decreases in prevalence of nephropathy, retinopathy, neuropathy, CKD, and stroke, and improving trends of care indicators from the two independent cohorts and re-examined data of patients enrolled in cohort 1. These trends were similarly observed in subgroups stratified according to age, gender, diabetes duration or BMI. In addition, the subanalysis limited to 10 clinics that participated in both cohorts indicated the same trend observed in the whole cohorts. These findings may suggest that the difference in the two cohorts is a function of time rather than of difference in the composition of the cohorts. Also in type 1 diabetes, we found for the first time that the prevalence of nephropathy, retinopathy and CKD was significantly decreased from 2004 to 2014.

Although randomized controlled trials have suggested benefits for inhibiting the development of diabetic microvascular complications,6–13 such decreases in the prevalence during a decade dealing with a large number of patients have not been adequately demonstrated in real world practice. To our knowledge, no studies have shown the prevalence of all three microvascular complications on the same patients and the differences of prevalence over time. Few studies showed secular trends of diabetic neuropathy over time, partly because the diagnostic criteria vary among the studies. For retinopathy, a large study from a UK community-based diabetic retinopathy screening program reported a reduction in sight-threatening retinopathy from 1990 to 2006, but prevalence of any retinopathy increased from 23.2% to 25.6%.25 Luki et al noted a decreasing incidence of CHD, stroke, end-stage renal disease, and death, and corresponding improvements in care indicators over a 13-year period from 2000 to 2012 using the Hong Kong national registry system; however, they failed to observe changes in the prevalence of albuminuria or retinopathy.18

The improvements in achieving targets for care indicators demonstrated in patients with type 2 diabetes were consistent with other studies employing the same target levels; HbA1c from 45% to 52% and BP from 38% to 47% in the USA,15 and HbA1c from 32% to 65% and BP from 32% to 47% in Germany.17 These trends may largely attribute to more frequent use of drugs including new agents. We assume that the decreases in prevalence of complications are likely reflections of a long-term improvement of care indicators, though it remains unclear. In the present study, the re-examined data of patients enrolled in cohort 1 were significantly improved from 2004 to 2014, whereas the prevalence of microvascular/macrovascular complications increased according to the increasing duration of diabetes with getting 10 years older, except for nephropathy. Thus, further studies are required to elucidate this critical issue.

Regarding albuminuria and eGFR, the trend we found was a significant decrease of ACR ≥30 mg/g Cr without parallel improvements in CKD both in patients with type 2 and type 1 diabetes of similar age. The National Health and Nutrition Examination Survey reported a decrease of ACR ≥30 mg/g from 33.5% in 1998 to 23.9% in 2009 in US adults with diabetes aged <65 years, and did not observe any decrease of eGFR <60 mL/min/1.73 m².26 In the JDDM follow-up study that observed patients with type 2 diabetes from 2004 to 2008, the regression rate from microalbuminuria to normoalbuminuria (28% per 4 year) was higher than the progression from normoalbuminuria to microalbuminuria (9% per 4 year), but the faster decline in eGFR was shown depending on the albuminuria levels.27 These may indicate that recent treatment advances still failed to improve GFR, and several studies have recently demonstrated the presence of normoalbuminuric renal impairment (CKD) in both type 2 and type 1 diabetes.28–32 The percentages of normoalbuminuric CKD in the present study, 7.9% in type 2 diabetes and 3.3% in type 1 diabetes, as demonstrated in table 4, were similar to those in other studies, in which the clinical features of patients with normoalbuminuric CKD were almost the same among the studies; they were older and predominant in women and non-smokers, and had less diabetic microvascular complications.28–32 The number of patients with normoalbuminuric CKD must further increase in the future because of increasing rate of regression of albuminuria as a consequence of increasing use of angiotensin receptor blockers, increasing age of the population and/or the longevity.30–33 We found, however, the prevalence itself was not prominently increasing over time at the same age range of patients with both type 2 and type 1 diabetes. Whether elderly patients with normoalbuminuric CKD are at a high risk of end-stage renal disease or CVD and need intensive intervention should be explored in the future.

To our knowledge, few studies have reported decreases in the prevalence of albuminuria, CKD or retinopathy over time for patients with type 1 diabetes until now. Management advances in insulin therapy as shown in table 1 have likely contributed to the improvement in HbA1c values with reducing glycemic variability. Even in patients with type 1 diabetes, slight increases of using antihypertensive and lipid-lowering drugs were observed. These have likely led to the decreases in microvascular complications. The decreased incidence of proteinuria, end-stage renal disease, and mortality in patients with type 1 diabetes appears to be in line with these findings.34–38
BMI values in the younger male and female patients with type 2 diabetes significantly increased from 2004 to 2014. Concomitantly, the rates for achieving treatment targets for HbA1c, BP and lipid in the younger patients were lower than in the elderly patients in 2014, and it may be alarming that the latter two values did not improve over time. The increase in BMI values and obesity was observed in our study and in other studies.14 17 39 This is important because obesity causes higher medical expenditure and poorer controls for blood glucose, BP, and lipid, and recently steatohepatitis is becoming a topic in such patients leading to liver cirrhosis, CVD, and cancer.38–41 These concerns may warrant weight reduction and strict control for younger adults with type 2 diabetes since they have more to gain from risk factor control because their life expectancy is longer and the potential for complications increases with the duration of diabetes. Their lower adherence and motivation to their lifestyle and medication remain a problem. Furthermore, it becomes more complicated if the cause of increased BMI is due to the more aggressive therapy of diabetes.

The strength of this study is that the prevalence of microvascular/macrovascular complications and assessment of care indicators were simultaneously evaluated with a larger number of patients than in other studies,14–17 and the trend over time was ensured by the re-examination as well as age-matched and sex-matched groups. In addition, the present results were based on medical records of daily clinical practice, whereas in most other studies, information regarding the diagnosis of diabetes, medications and complications were self-reported.14–17 These facts have firmly contributed to investigating the secular trend in the present study. It was of interest that the percentage of current smokers decreased in men and increased in women with type 2 diabetes; the effect of smoking trend on prevalence of complications should be explored in future studies.

There are some limitations that should be described. Although the study was performed in primary care settings, a selection bias may have been caused by physicians voluntarily participating in this study. They were general practitioners specializing or being interested in diabetes care. Thus, the control levels of diabetes care in patients treated by them might be better than those by other general practitioners, because they might take care of patients more aggressively than the others. Conversely, they might take care of more patients with poor glyemic controls or severe complications than the others. These points might influence the results of this study. Also, this study was basically performed to compare the two independent cohorts over a decade. Thus, we cannot completely exclude a possibility that the findings in this study were due to a difference in the composition of the cohorts, although the trends were similarly observed in subgroups stratified according to age, gender, diabetes duration or BMI. Next, there was a lack of information on dietary and exercise behavior, adherence to medication, and socioeconomic status. These factors are likely to affect the outcome of complications and care indicators.42 43 Finally, with respect to comparison between baseline and re-examined data in cohort 1, the re-examined data were limited to those who continuously visited the participating clinics. Thus, we should acknowledge that the current data of those lost to follow-up were not available.

In conclusion, we observed declining trends in diabetic microvascular complications with improvement of diabetes care indicators, such as therapeutic goal attainment and habit of smoking in patients with type 2 and type 1 diabetes. Increasing BMI levels with lower rates for achieving therapeutic goals in younger patients with type 2 diabetes remains a concern. Importantly, although the improvement in prevalence of vascular complications and care indicators may lead to longevity in the diabetic population, this could increase ageing-related problems.
Pathophysiology/Complications

REFERENCES

1. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. *Lancet* 2016;387:1513–30.

2. Saadine JB, Honeycutt AA, Narayan KM, et al. Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005-2050. *Arch Ophthalmol* 2008;126:1740–7.

3. Selvin E, Parrinello CM, Sacks DB, et al. Trends in prevalence and control of diabetes in the United States, 1988-1994 and 1999-2010. *JAMA* 2009;301:366–71.

4. Brownring JR, Hughes CO, Burleigh D, et al. Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study. *Lancet Diabetes Endocrinol* 2016;4:588–97.

5. Motthof ME, Delano RA, Franz MJ, et al. Nephropathy in diabetes. *Diabetes Care* 2004;27(Suppl 1):S79–83.

6. Klein BE. Overview of epidemiologic studies of diabetic retinopathy. *Ophthalmic Epidemiol* 2007;14:179–83.

7. Tesfaye S. Recent advances in the management of diabetic distal symmetrical polyneuropathy. *J Diabetes Invest* 2012;3:33–42.

8. Nathan DM, Gethum S, Lachin J, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 1993;329:977–86.

9. The UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 1998;352:837–53.

10. Holman RR, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med* 2008;359:1577–89.

11. Nathan DM, Cleary PA, Backlund YJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. *N Engl J Med* 2005;353:256–65.

12. Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. *Lancet* 2008;371:117–25.

13. The UK Prospective Diabetes Study Group. Tight blood pressure control and reduced macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. *BMJ* 1998;317:703–13.

14. Ali MK, Bullard KM, Saadine JB, et al. Achievement of goals in U.S. diabetes care, 1999-2010. *N Engl J Med* 2013;368:1613–24.

15. Stark Casagrande S, Fradkin JE, Saydah SH, et al. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010. *Diabetes Care* 2013;36:2271–9.

16. Kuznik A, Mandekian J. Trends in utilization of lipid- and blood pressure-lowering agents and goal attainment among the U.S. diabetic population, 1999-2008. *Cardiovasc Diabetol* 2011;10:31.

17. Du Y, Heidemann C, Sacherath Rosario A, et al. Changes in diabetes care indicators: findings from German National Health Interview and Examination Surveys 1997-1999 and 2008-2011. *BMJ Open Diab Res Care* 2015;3:e000135.

18. Luk AOY, Hui EMT, Sin MC, et al. Declining trends of Cardiovascular-Renal Complications and Mortality in Type 2 Diabetes: The Hong Kong Diabetes Database. *Diabetes Care* 2017;40:928–35.

19. Yu NC, Su HY, Chiou ST, et al. Trends of ABC control 2006-2011: a National Survey of Diabetes Health Promotion Institutes in Taiwan. *Diabetes Res Clin Pract* 2015;114:122–8.

20. Rathmann W, Scheerer M, Rohwedder K, et al. Changes in patient characteristics, glucose lowering treatment, glycemic control and complications in type 2 diabetes in general practices (Disease Analyzer, Germany: 2008-2016). *Postgrad Med* 2018;130:244–50.